Major Depressive Disorder

Vortioxetine appeared to reduce cognitive impairment among patients with major depressive disorder, according to results of a systematic review published in Journal of Clinical Psychiatry.

Decoglurant appeared well-tolerated but did not produce any antidepressant or procognitive effects among patients with partially refractory major depressive disorder, according to study results published in Journal of Clinical Psychiatry.

Adjunctive transdermal testosterone was well tolerated but not more effective than placebo for symptoms of depression, fatigue or sexual dysfunction, according to study results published in American Journal of Psychiatry.

Patients with PTSD had similar levels of major depressive disorder response and remission with transcranial magnetic stimulation, or TMS, as patients without PTSD, according to study findings published in Journal of Clinical Psychiatry.

Area-level artificial light at night, or ALAN, may negatively affect sleep patterns and increase risk for mood and anxiety disorders among adolescents, according to results of a study published in JAMA Psychiatry.

Patients with major depressive disorder and comorbid PTSD who were unresponsive to antidepressant treatment exhibited a positive response to three “next-step” treatments, according to a study published in Journal of Clinical Psychiatry.

Individuals with depression who experienced loss of interest and reduced activity appeared to benefit more from aripiprazole augmentation than escitalopram monotherapy, according to findings published in Journal of Clinical Psychiatry.

Antidepressants augmented with intranasal esketamine appeared effective among patients with major depressive disorder who were treatment-resistant or acutely suicidal, according to study results published in Journal of Clinical Psychiatry.

Researchers have uncovered important factors associated with the switch from mania to depression among individuals with bipolar 1 disorder, according to results of a prospective observational study published in Journal of Clinical Psychiatry.

Use of a combinatorial pharmacogenomic test appeared associated with improved outcomes among patients with major depressive disorder, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.